Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial

  • Virginia A. Stallings,
  • Alyssa M. Tindall,
  • Maria R. Mascarenhas,
  • Asim Maqbool,
  • Joan I. Schall
  • Article
  • Metrics
  • Comments
  • Media Coverage

The Competing Interests statement is incorrect. The correct Competing Interests statement is as follows: LXS (now known as Encala™) was a product of BioMolecular Products, Inc and was used for the clinical trial. Envara Health was founded in 2018 to develop therapeutic nutrition products related to the licensed LXS (now Encala™) technology. After study completion, VAS co-founded Envara Health and serves as a consultant.

Reference

  1. 1. Stallings VA, Tindall AM, Mascarenhas MR, Maqbool A, Schall JI (2020) Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial. PLoS ONE 15(5): e0232685. https://doi.org/10.1371/journal.pone.0232685 pmid:32384122